top of page
Report.png
Neurostimulation Devices Market

Neurostimulation Devices Market Size, Share, Competitive Landscape and Trend Analysis Report by Product, Application and End Use: Global Opportunity and Industry Forecast (2025-2032)

Report ID:

1177

Industry:

Healthcare

Published on:

March 2026

Neurostimulation Devices Market had a value of USD 14.62 billion in 2025 and expected it to hit USD 30.97 billion by 2032, with a CAGR of 11.32 % through the forecast period.

Neurostimulation Devices Trends and Analytical Insights -

  • North America Neurostimulation Devices Market was the largest revenue generating region market in year 2025, with market share accounted for 42.75 %.

  • In 2025, By Product segment, Spinal Cord Stimulators segment dominated the Neurostimulation Devices Market, accounted for 38.42 % market shares.

  • Leading Key players for Neurostimulation Devices Market in 2025 was Abbott Laboratories, Smith’s Medical and B. Braun Melsungen AG

Neurostimulation Devices Market Size & Forecast

  • Market Size 2024: USD 14.62 Billion

  • Projected Market Size 2032: USD 30.97 Billion

  • CAGR (2025-2032): 11.32 %

  • North America: Dominating market in 2025

Neurostimulation Devices Market Overview

Global neurostimulation devices market was encompassing the global neurostimulation devices industry, which was being used as an effective method of administering electrical impulses to selected parts of the body (or the brain) to treat a variety of neurological disorders and chronic illnesses. Neurostimulation devices were being comprised of pulse generators, electrodes and external control devices which were being designed to transition from short-duration (or transient) electrical stimulation of specific nerves to more sustained (or continuous) stimulation of those same nerves. These technologies were being increasingly employed across a wide range of therapy areas, including: pain management, movement disorders, epilepsy and other psychiatric disorders. Hospitals and specialty clinics were beginning to utilize neurostimulation therapies as a cost-effective alternative to drug therapies. Through 2018-2024, there was going to be an increase of more than 35% in the number of clinical studies related to neurostimulation therapies, which was continuing to drive innovation of new devices and was increasing investment in research. Healthcare organizations were focusing on driving improved outcomes through advanced neuromodulator solutions to improve patient outcomes and reduce dependence on long-term medication. Neurostimulation devices were becoming significant components of neurological treatment plans.

The neuromodulation devices market was also suffering from increased incidence of neurological disorders and increasing technology developments to implantable medical devices. Neurological health studies that were being completed between 2020 and 2024 were finding that over 10 million people worldwide were being diagnosed with Parkinson's disease and nearly 50 million people were suffering from epilepsy. As manufacturers were providing smaller implantable stimulation devices as a result of wireless programming advancements that were occurring, hospitals were noting improvements in treatment efficiency in patients who were receiving electrical stimulation therapy as part of their conventional treatment. In 2020, over 2024 hospitals globally were implementing neuromodulation programs in specialty neurological units. Additionally, improvements in healthcare infrastructure and increased physician training programs were supporting a greater level of clinical adoption that was occurring across more regions globally. These developments were increasing treatment access while continuing to evolve the neuromodulation devices market across a wide range of healthcare systems.

Neurostimulation Devices Market Dynamic’s

The Neurostimulation Devices Market was growing rapidly as a result of the increasing prevalence of neurological and chronic pain conditions. According to research that was being conducted between 2019 and 2024, approximately 20% of the adult population worldwide was suffering from chronic pain that was requiring long-term treatment. Spinal cord and deep brain stimulation devices were increasingly being used by neurologists as alternative treatments for patients with these types of conditions. Clinical studies were showing that patients who were receiving neurostimulation treatment were reporting an average reduction in their pain levels of between 2019 and 2024, within one year of starting the therapy. Health care companies were also noticing improvements in their patients' mobility and quality-of-life as a result of receiving neurostimulation therapy. Research funding for innovative neurological treatments was increasing in major health care economies; As of 2019, Neuromodulation Research at more than one hundred and twenty 2024 colleges and universities was being funded through these grants. Improvements in battery technology, electrode design, and programming of wireless devices were continuing to increase the effectiveness and reliability of these therapies.

The Neurostimulation Devices sector was experiencing challenges both operationally and in terms of clinical practices that were impacting the rates at which these devices were being accepted. Procedures that were using implantable neurostimulation devices were typically requiring both specialized surgical skills and an advanced hospital environment to complete. Training programs were expanding to train neurosurgeons on implanting neurostimulation devices but many surgeons who were being trained to implant these types of devices were still not practicing in many healthcare systems. Implanting a neurostimulation device was requiring that a thorough neurological assessment be performed on the patient prior to completing the procedure, followed by ongoing monitoring of the patient's health over time after having the device implanted. Despite these challenges, large-scale opportunities were existing through advances in technology and digital integration into the neurostimulation market. Medical device manufacturers were developing closed-loop neurostimulation systems that were allowing for electrical signal delivery to change automatically based on measurements obtained from the patient's nerve activity. Between 2021 and 2024, more than 30 patent applications for neuromodulation devices were being filed with the patent office that were utilizing methods of controlling adaptive stimulation algorithms and remote monitoring systems. Telemedicine platforms were being utilized to conduct follow-up consultations with patients who were having implanted devices which was helping improve the management of therapy and improve access for physicians to treat these patients.

Continuous technological advancements were being realized throughout 2023 in the Neurostimulation Devices marketplace. These advancements were being driven by research organizations that were conducting clinical studies and manufacturers that were developing and producing global medical devices. As of 2023 over 70 new neurostimulation device models were being reviewed for regulatory approval in all major healthcare markets across the world. Manufacturers were producing rechargeable implantable pulse systems that were extending the operational lifespan of the devices from a previous maximum of approximately 3 years to near 10 years. Clinical studies in 2023 were also evaluating the use of neurostimulation therapy to treat some psychiatric disorders such as depression and anxiety. Beginning in 2023, over 25 new clinical studies were going to be evaluating the application of vagus nerve stimulation for treatment-resistant major depression disorder. Many healthcare organizations were also using digital programming applications that were enabling physicians to use wireless systems to adjust neuro-stimulation parameters.

Neurostimulation Devices Market Segment Analysis

The Neurostimulation Devices Market segmented into By Product, Application and End Use.

By Product,

Based on the product, the market was segmented into Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, Gastric Electrical Stimulation, and Others. In 2025, the Spinal Cord Stimulators segment dominated the Neurostimulation Devices Market, accounting for around 38.42 % of the total market share. Chronic Pain Management Spinal Cord Stimulators were being found in numerous Neurology and Orthopedic Clinic Chronic Pain Management Programs. Medical records between 2022 and through 2024 were revealing that over 2 million patients from around the world were receiving Spinal Cord Stimulation Therapy. Many hospitals were implementing these devices for long-term pain control for patients with Failed Back Surgery Syndrome and patients with Neuropathic Pain Conditions. The clinical data was showing that Spinal Cord Stimulation procedures were having a positive effect on opioid dependence within Pain Management programs. Continued advancements in electrode technology and rechargeable pulse generators were enhancing the efficiency of long-term therapy. These positive clinical outcomes were resulting in the increased implementation of Spinal Cord Stimulation Technologies in the Neurostimulation Devices market.

By Application,

Based on the application, the market was segmented into Parkinson’s Disease, Chronic Pain, Migraine, Epilepsy, Tremor, Depression, Urinary & Fecal Incontinence, and Others. In 2025, the Chronic Pain segment dominated the Neurostimulation Devices Market, accounting for around 41.23 % of the total market share. Chronic pain disorders were affecting millions globally, leading to an increased demand for neuromodulation treatments. A healthcare study published between 2020 and 2024 was showing that over 1.5 billion people worldwide were suffering from a type of chronic pain condition. Neurostimulation therapies were providing patients with long-term pain management through the use of electrical stimulation to specific nerve pathways. Pain management clinics were utilizing an increasing number of implantable neurostimulation devices as alternatives to long-term medications. Doctors were reporting higher patient satisfaction among those receiving spinal cord stimulation or peripheral nerve stimulation therapy. These results were demonstrating to healthcare providers the clinical benefits of utilizing neuromodulation therapies in their practices and were encouraging them to include neuromodulation therapies in the Neuromodulation Devices Market.

Neurostimulation Devices Market Region Analysis

In 2025, North America region dominated the Neurostimulation Devices Market with a share of around 42.75 % of the global market. This region was being led by an Advanced Health Care Infrastructure and High Level of Neurological Research Programs; hospitals throughout the United States and Canada were implementing new neuromodulation treatment programs across specialized departments of neurology; clinical training for Neurosurgeons was expanding the availability of neurosurgery procedures in U.S. and Canadian hospitals. Regulatory Agencies were approving implantable stimulation technologies between the years of 2021 to 2024; Medical device companies were actively providing clinical trials for their products across the entire region; Healthcare expense spending for neurological disorders was steadily increasing, with numerous amounts of money going into research and development of neuromodulation therapies; Patient awareness of new therapies in major metropolitan healthcare systems was improving; Advances in healthcare were continuing to support ongoing improvement and adoption throughout the Neurostimulation Devices Market.

Neurostimulation Devices Market Competitive Analysis

Manufacturers of neurostimulation devices around the world were competing primarily through technological advancement and clinical studies, which was leading to the development of more sophisticated implantable neurostimulation systems that were having longer-lasting batteries and were being more precise in their ability to transmit electrical impulses to neural tissue. There was also being an increased focus on establishing strategic collaborations with hospitals and neuroscientific research institutions to enhance product development and support clinical trials; thus, these manufacturers were allowing themselves to better meet their customer needs. With both wireless programming capabilities as well as the introduction of rechargeable stimulation units being added to these manufacturers' product lines, this was continuing to provide ease-of-use for patients. In addition, the continued diversification of product lines and the availability of regulatory approvals were helping these manufacturers establish a more competitive position. Furthermore, all of these manufacturers were utilizing ongoing research and development programs combined with partnerships with neurosurgeons in order to create new treatment opportunities through the utilization of neurostimulation devices.

Neurostimulation Devices Market Scope:

Key Players –

Frequently Ask Questions –

1)    What is the Neurostimulation Devices Market?

Ans - The Neurostimulation Devices Market was referring to the industry focused on medical devices that were delivering electrical stimulation to nerves or brain regions for treating neurological disorders. 

2)    What conditions were treated in the Neurostimulation Devices Market?

Ans - The Neurostimulation Devices Market was supporting treatment for conditions such as chronic pain, Parkinson’s disease, epilepsy, migraine, and urinary incontinence. 

3)    Which product type dominated the Neurostimulation Devices Market?

Ans - Spinal cord stimulators were dominating the Neurostimulation Devices Market as they were widely used in chronic pain management therapies.

4)    What technological developments were influencing the Neurostimulation Devices Market?

Ans - The Neurostimulation Devices Market was advancing through rechargeable implantable devices, wireless programming systems, and adaptive stimulation technologies.

Which region led the Neurostimulation Devices Market?

Ans - North America was leading the Neurostimulation Devices Market through strong healthcare infrastructure, advanced neurological research, and increasing clinical adoption.

Report Payment

Single User:
$4199
Spreadsheet:
$2900
Corporate User:
$5500
bottom of page